July 30, 2021

Bioventus to Acquire Misonix, Enhance Surgical Solutions

Bioventus to Acquire Misonix, Enhance Surgical Solutions
The merger will create a company positioned with products and specialized salesforces serving hospital, ambulatory surgical center and office care settings.
February 8, 2021

Seikagaku Weathers Another Quarter of Losses

Seikagaku Weathers Another Quarter of Losses
Despite some volume increases in Japan and the U.S., the company continued to slide due to COVID and erosion of the 5-injection HA market.

Member-Only Content

February 4, 2021

Bioventus Launches New Initial Public Offering

Bioventus Launches New Initial Public Offering
The company announced its second IPO try today with an initial public offering of its Class A common stock targeting $100 million in proceeds.
December 22, 2020

Study Update: Bone Therapeutics’ Phase III Knee Trial

Study Update: Bone Therapeutics’ Phase III Knee Trial
The company has completed recruitment and treated all patients in its Phase III study with the viscosupplement, JTA-004, in patients with knee osteoarthritis.
November 10, 2020

Bioventus Knee Products to be Available through CVS Caremark

Bioventus Knee Products to be Available through CVS Caremark
CVS Caremark manages the drug benefits for more than 40 million lives, which includes the prescription drug benefits of 6 million Aetna members.
September 30, 2020

Seikagaku Signs Marketing Agreement for OA Treatment

Seikagaku Signs Marketing Agreement for OA Treatment
Eisai and Seikagaku will co-develop and market the SI-613 sodium hyaluronate therapeutic agent in South Korea for the treatment of knee osteoarthritis.
September 22, 2020

Bioventus Reaches Milestone with DUROLANE Worldwide

Bioventus Reaches Milestone with DUROLANE Worldwide
DUROLANE injection treats knee osteoarthritis in patients who have failed to respond adequately to conservative non-pharmacological therapy or analgesics.
August 3, 2020

Anika Inorganic Growth Offsets COVID Declines

Anika Inorganic Growth Offsets COVID Declines
Sports medicine revenue from the acquisition of Parcus Medical and Arthrosurface helped Anika navigate the low point of the COVID orthopedic market in 2Q20.

Member-Only Content

June 15, 2020

Bioventus Selects DUROLANE Distributor in Russia

Bioventus Selects DUROLANE Distributor in Russia
DUROLANE single-injection hyaluronic acid treats pain associated with osteoarthritis in the knee, hip and small joints.
March 18, 2020

Orthobiologics Face Pressure from Lack of Clinical Evidence

Orthobiologics Face Pressure from Lack of Clinical Evidence
In the race to capitalize on patient-driven interest in stem cells, biologic solutions and “regeneration” of a more vital, healthy and functional body, there has been an explosion of offerings that lack scientific controls, validity and meaningful evidence.
January 6, 2020

Seikagaku and Ono Submit NDA for Injectable OA Treatment in Japan

Seikagaku and Ono Submit NDA for Injectable OA Treatment in Japan
Seikagaku and Ono Pharmaceutical submitted a new drug application for manufacturing and marketing approval for ONO-5704/SI-613 injectable in Japan for the treatment of OA.
December 18, 2019

Bioventus Secures BCBS Coverage for OA Treatments

Bioventus secured preferred access to DUROLANE, GELSYN-3 and SUPARTZ FX to treat knee OA pain for certain Blue Cross Blue Shield of Michigan patients. 
March 22, 2019

Seikagaku Launches HyLink in Italy

Seikagaku commenced Italy launch of HyLink® single-injection viscosupplement for knee osteoarthritis.
February 19, 2019

Seikagaku and Ono Announce Positive Study Results

Seikagaku and Ono Pharmaceutical obtained positive topline results from a Phase III confirmatory study of an HA/NSAID formulation in the treatment of knee OA.
January 29, 2019

Bioventus Launches DUROLANE in Malaysia

Bioventus launched DUROLANE® single-injection joint fluid osteoarthritis therapy in Malaysia, through exclusive distribution partner Athrotech.
January 22, 2019

OrthogenRx Launches TriVisc in the US

OrthogenRx commenced U.S. launch of TriVisc® sodium hyaluronate for the treatment of knee osteoarthritis pain.
December 5, 2018

Anika Therapeutics Distributes HA-based Therapies Again

Anika Therapeutics resumed global distribution of HYALOFAST and HYALOGRAFT-C therapies for cartilage repair, following a voluntary product recall.
November 6, 2018

Bone Therapeutics to End Phase III PREOB Study

The Data and Safety Monitoring Board recommended discontinuation of the Phase III hip osteonecrosis study of Bone Therapeutics' PREOB viscosupplement, following interim analysis of results.
October 17, 2018

Bone Therapeutics Reports Results of Viscosupplement Study

Bone Therapeutics' first efficacy study of the JTA-004 viscosupplement to treat knee OA showed that a single injection delivered higher pain reduction vs. a reference product.
October 2, 2018

Bioventus Signs Pfizer as Exclusive DUROLANE Distributor in Brazil

Bioventus received ANVISA approval to market DUROLANE® single-injection in Brazil to treat hip osteoarthritis. Pfizer will serve as its exclusive distribution partner.
April 25, 2018

Fidia Presents HYMOVIS Viscosupplement Study Data

Studies indicate that Fidia's HYMOVIS® viscosupplement enhanced cartilage volume and thickness in patients suffering from symptomatic knee OA.
April 20, 2018

Orthobiologics: Conversations with CEOs

At AAOS, we sat down with the CEOs of Bioventus and Histogenics to ask about opportunities that their companies are embracing, as well as the health of the orthobiologics market. Both mentioned advancements in therapies demonstrated through clinical trials and outcomes, and both discussed the importance of keeping younger, active patients healthy and mobile. Here we recap a portion of those conversations.
March 5, 2018

Bioventus Launches Durolane in the US

Bioventus commenced U.S. launch of DUROLANE single-injection hyaluronic acid to treat knee OA pain. 
February 12, 2018

Bioventus/Seikagaku Extend SUPARTZ FX Distribution Agreement

Bioventus extended its agreement to exclusively distribute Seikagaku's SUPARTZ FX five-injection hyaluronic acid in the U.S. through May 2028.
January 26, 2018

DePuy Synthes Reports 4Q17 and 2017 Revenue

ORTHOWORLD estimates DePuy Synthes' 4Q17 orthopaedic revenue at US $2,245.7MM, +0.3% vs. 4Q16, with 2017 revenue of $8,791.5MM, +0.4% vs. 2016.

Member-Only Content

October 30, 2017

Anika Therapeutics 3Q17 Revenue +7% vs. 3Q16

Anika Therapeutics posted 3Q17 orthobiologic revenue of US $24.0MM, +7.0% vs. 3Q16, and year-to-date revenue of $68.7MM, +5.2% vs. the prior year.

Member-Only Content

October 26, 2017

Anika Fully Enrolls Second Phase III CINGAL Trial

Anika Therapeutics completed enrollment in its second pivotal Phase III trial evaluating CINGAL® HA/corticosteroid viscosupplement for the treatment of knee osteoarthritis symptoms.
October 23, 2017

FzioMed Receives FDA Approval Oxiplex Study

FzioMed received FDA approval to conduct a small confirmatory study of Oxiplex® synthetic viscoelastic gel, examining its use following lumbar surgery.
October 17, 2017

Anika Gains Australia Approval for MONOVISC Viscosupplement

Anika Therapeutics received Australia regulatory approval to market MONOVISC® single-injection viscosupplement for the treatment of osteoarthritis pain in all synovial joints. 
September 5, 2017

Bioventus Receives FDA Premarket Approval for DUROLANE

Bioventus received FDA premarket approval for DUROLANE single-injection hyaluronic acid to treat pain associated with knee osteoarthritis.
August 8, 2017

Study Results: Anika’s HYALOFAST in Knee Cartilage Lesions

Studies indicate that Anika Therapeutics' HYALOFAST® scaffold + autologous adult MSCs present a viable option to treat knee cartilage lesions, regardless of patient age.
August 2, 2017

Zimmer Biomet Orthopaedic Revenue for 2Q17

ORTHOWORLD estimates Zimmer Biomet 2Q17 orthopaedic revenue of US $1,816.0MM, +2.6% from 2Q16, and 1H17 revenue of $3,652.1MM, +3.7% vs. 1H16.

Member-Only Content

May 23, 2017

CINGAL Phase III Data Demonstrates Efficacy and Safety to Treat Knee OA Pain

Phase III study results demonstrated that Anika Therapeutics' CINGAL® provided superior immediate and short term OA pain relief after injection vs. hyaluronic acid alone, and superior relief at 26 weeks vs. saline. 
May 17, 2017

Seikagaku Enters Collaboration on SI-613 in Japan

Seikagaku entered into a basic co-development and marketing collaboration with Ono Pharmaceutical in Japan for SI-613 for the treatment of osteoarthritis.
February 2, 2017

FDA Approves Expanded 26-week Efficacy Claim for Gel-One to Knee OA Pain

Zimmer Biomet announced FDA approval of an expanded 26-week efficacy claim for single-injection Gel-One® Cross-linked Hyaluronate viscosupplement for the treatment of knee pain associated with osteoarthritis.
January 17, 2017

New Durolane Agreement in Russia

Bioventus selected MEDSERVICE to distribute DUROLANE® single-injection joint fluid in Russia. 
December 19, 2016

Anika Gains CE Mark Approval for ORTHOVISC-T

Anika Therapeutics received CE Mark approval for ORTHOVISC®-T injection indicated to relieve pain and restore function in tendons affected by chronic lateral epicondylosis.
December 14, 2016

New DUROLANE Agreement

Bioventus entered into an agreement with Galderma to bring DUROLANE knee osteoarthritis treatment to the U.S.
May 19, 2016

Anika Therapeutics Launches CINGAL in Canada

Anika Therapeutics announced Canada launch of CINGAL® viscosupplement, cleared to treat knee osteoarthritis pain. CINGAL will be marketed by Pendopharm.
February 25, 2016

Fidia to Introduce Hymovis, Next-Generation Hyaluronan

Fidia will commence U.S. launch of Hymovis® 2-injection highly viscoelastic hyaluronan, indicated to treat knee OA pain.
February 23, 2016

Bioventus Acquires U.S. Distribution Rights to GELSYN-3 HA Injection

Bioventus entered into a multi-year agreement with Institut Biochimique, gaining exclusive U.S. distribution rights for GELSYN-3™ 3-injection hyaluronic acid product for pain relief associated with knee OA.
January 25, 2016

Anika Responds to CINGAL’s Drug Classification

In late 2015, FDA assigned Anika Therapeutics' CINGAL to the Center for Drug Evaluation and Research (CDER) and not the Center for Device and Radiological Health (CDRH) for its premarket review-a decision with which Anika's leadership says it disagrees.